November 2025 delivered a sharp reality check for psychedelic microdosing while macrodose studies advanced treatment options for depression, PTSD, and end-of-life distress.
Psychedelic Policy News from November 2025 where we cover veterans getting access, faster psilocybin approval, and micro(dosing) results.
In this Delphi Insight Session, Lia Mix shares her journey with trauma and healing, and how Delphi and IHPI are advancing Ibogaine therapy.
New psychedelic studies from October show 5-year safety data from esketamine, the importance of set & setting, and microdosing null-results.
New psychedelic studies from September show psilocybin for addiction, LSD for anxiety, and group therapy for burnout, guiding clinical and policy integration.
Kate Reynolds from Rocky Mountain Poison and Drug Safety (RPMDS) discusses how NSIHT tracks real world psychedelic use nationwide.
Join Lia Mix, CEO of Delphi, and Floris Wolswijk, Senior Policy and Research Partner at Delphi, for the third Delphi Insight Session on reimbursement pathways for psychedelic therapies in Europe.
The latest research on psychedelic-assisted therapies in August provides critical insights into economic feasibility, implementation models, and clinical effectiveness across diverse patient groups.
New psychedelic studies highlight cross-indication applicability of MDMA-assisted therapy, risks with naturalistic use, and potential life-extending effects of psilocybin.
New psychedelic studies highlight durable effects of psilocybin therapy, Delphi consensus, and pivotal Phase II and III trials.
